Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) COO Jeetinder Singh Mahal sold 900 shares of the firm's stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $22.11, for a total value of $19,899.00. Following the completion of the sale, the chief operating officer now directly owns 25,009 shares in the company, valued at $552,948.99. The trade was a 3.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Jasper Therapeutics Price Performance
Shares of JSPR opened at $20.47 on Friday. The business's 50 day moving average price is $20.91 and its 200-day moving average price is $20.89. Jasper Therapeutics, Inc. has a 52 week low of $4.00 and a 52 week high of $31.01.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on JSPR. BMO Capital Markets started coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an "outperform" rating and a $63.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. HC Wainwright reaffirmed a "buy" rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Cantor Fitzgerald reissued an "overweight" rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Finally, Evercore ISI reaffirmed an "outperform" rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $73.38.
Amazon coin set to soar 25X – starting December 16th?
From True Market Insiders | Ad
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon.
And one team of crypto experts has identified it as the most promising crypto of 2024.
You can see all of the details surrounding the #1 Crypto of 2024
>3-Cent Amazon Coin<
Read Our Latest Stock Analysis on JSPR
Hedge Funds Weigh In On Jasper Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of JSPR. Samsara BioCapital LLC increased its stake in Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company's stock valued at $10,997,000 after purchasing an additional 59,642 shares in the last quarter. Ally Bridge Group NY LLC increased its position in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock valued at $7,514,000 after acquiring an additional 180,852 shares in the last quarter. Braidwell LP purchased a new position in Jasper Therapeutics in the 3rd quarter worth approximately $9,091,000. Bank of New York Mellon Corp bought a new position in Jasper Therapeutics in the 2nd quarter valued at approximately $740,000. Finally, Verition Fund Management LLC purchased a new stake in Jasper Therapeutics during the 3rd quarter valued at $477,000. 79.85% of the stock is currently owned by institutional investors.
Jasper Therapeutics Company Profile
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
